Business context and reporting period
Entity clarification: Although the request identifies Senti Biosciences Holdings, Inc., this filing is the fiscal 2021 Form 10-K of Dynamics Special Purpose Corp. (Nasdaq: DYNS), a SPAC formed to pursue a business combination. It is not Senti’s standalone annual report. The reporting period runs from Dynamics’ March 1, 2021 inception through December 31, 2021; the filing was signed March 7, 2022.
Dynamics completed its IPO on May 28, 2021, raising $230.0 million, and placed $230.0 million in its trust account. On December 19, 2021, it agreed to combine with Senti Biosciences, Inc. Senti was to become a wholly owned subsidiary, with the combined company expected to use the name Senti Biosciences, Inc. and ticker SNTI. The transaction had not closed as of this filing.
Financial results and position
| Metric | Period or date | Value |
|---|---|---|
| Operating revenue | Inception to Dec. 31, 2021 | None |
| Operating and formation costs | Inception to Dec. 31, 2021 | $3.702 million |
| Franchise tax expense | Inception to Dec. 31, 2021 | $163,839 |
| Trust-account interest and dividend income | Inception to Dec. 31, 2021 | $8,784 |
| Net loss | Inception to Dec. 31, 2021 | $3.857 million; $0.17 per share for both Class A and Class B |
| Operating cash used | Inception to Dec. 31, 2021 | $1.142 million |
| Cash outside trust | Dec. 31, 2021 | $889,323 |
| Investments in trust | Dec. 31, 2021 | $230.009 million |
| Working capital deficit | Dec. 31, 2021 | $1.985 million |
| Total liabilities | Dec. 31, 2021 | $10.332 million, including $7.050 million deferred underwriting fees |
The company reported no operating cash flows from a revenue-generating business, no off-balance-sheet arrangements, and no debt outstanding at year-end. The filing provides no prior comparable operating period because the company was formed in 2021; therefore, a year-over-year comparison is not available. Profit margins are not meaningful for this pre-combination SPAC.
Material changes and proposed Senti transaction
- The underwriter waived $1.0 million of deferred IPO underwriting fees in December 2021, reducing the remaining fee to $7.05 million.
- The proposed merger values Senti’s equity at $240 million, payable in Dynamics Class A shares. Senti holders may earn up to 2.0 million additional shares if specified post-closing share-price thresholds of $15 and $20 are met.
- Private investors subscribed for 6.68 million shares at $10 per share, or $66.8 million, subject to closing conditions. Senti’s closing condition includes at least $150 million of Available Closing Cash, after applicable redemptions and taking account of PIPE funds.
- Investors agreed not to redeem 8,691,655 public shares in aggregate. In connection with those commitments, the sponsor agreed to forfeit 965,728 Class B shares, with an equivalent number of Class A shares to be issued to those investors if the merger closes.
- The agreement was amended on February 12, 2022, including changes relating to certain Senti options. Closing remained subject to stockholder approvals, regulatory clearance, Nasdaq listing approval, an effective registration statement, minimum net tangible assets of $5,000,001, and other conditions; completion was not assured.
Outlook, risks and unusual items
- Liquidity and going concern: The auditor’s report includes an explanatory paragraph expressing substantial doubt about Dynamics’ ability to continue as a going concern. Management cited limited cash outside the trust, a working capital deficit, and ongoing transaction costs. Management expected the Senti transaction to address the uncertainty, but acknowledged no assurance it would close. The financial statements include no adjustments for a possible failure to continue as a going concern.
- Trust and deadline: Dynamics had until May 28, 2023 to complete a business combination. If unsuccessful, it generally must redeem public shares from the trust and liquidate. The expected redemption was approximately $10 per share, but creditor claims, asset-value declines, taxes, or other circumstances could reduce the amount.
- Transaction funding and dilution: Redemptions could prevent the $150 million cash condition from being met. Additional financing may be unavailable or dilutive; the merger consideration, PIPE issuance, founder-share conversion and potential awards can dilute existing holders.
- Conflicts and incentives: Sponsor and insiders agreed to vote their shares in favor of a business combination and waived redemption rights on specified holdings. Founder shares were acquired for a nominal price, creating incentives that may differ from public shareholders’ interests. The filing’s illustrative calculation estimated $7.81 per share after a hypothetical combination under stated assumptions; it is not a forecast or transaction-specific valuation.
- Controls and restatements: Management concluded disclosure controls were ineffective and identified a material weakness in accounting for complex financial instruments. Prior financial statements were restated for the presentation of redeemable Class A shares. Remediation was planned, with no assurance it would be effective. The 2021 10-K did not include management’s internal-control assessment or auditor attestation due to the transition rules for newly public companies.
- Other risks: The filing highlights third-party claims against the trust, uncertainty about sponsor indemnification capacity, COVID-19 effects, competition for targets, regulatory and intellectual-property risks relevant to life sciences, and the risks of combining with a single development-stage business.
- Accounting and contingencies: The company reported no material pending litigation. A $1.0 million financial-advisory fee and a placement-agent fee equal to 4% of PIPE proceeds were payable upon the relevant transaction closing.
Important facts for investors to verify
- Confirm the filing issuer: this is Dynamics Special Purpose Corp.’s 2021 10-K, not Senti’s standalone 10-K.
- Check subsequent SEC filings for the merger’s closing status, final redemption levels, Available Closing Cash, PIPE funding, and satisfaction or waiver of closing conditions.
- Review Senti’s audited financial statements and its clinical, regulatory, cash runway, intellectual-property and operating risks in the merger registration materials; those Senti-specific financial results are not presented here.
- Track remediation of the material weakness and any later control evaluations or restatements.
- Assess dilution, lock-ups, the sponsor’s share forfeiture, contingent earnout shares, transaction fees, and the effect of redemptions on cash available after closing.
- Verify the trust balance, creditor claims and sponsor’s ability to meet its indemnification obligations before relying on any stated redemption value.